| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CAKUT3; RIP140 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human NRIP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NRIP1抗体的模拟参考文献示例(注：文献为虚构示例，仅供格式参考)：
---
1. **文献名称**：*NRIP1 Antibody-Based Detection of RIP140 in Estrogen Receptor-Positive Breast Cancer*
**作者**：Smith A, et al.
**摘要**：研究利用兔源多克隆NRIP1抗体，通过Western blot和免疫组化技术，证实NRIP1在乳腺癌中与雌激素受体α(ERα)共定位，并增强肿瘤细胞对雌激素的敏感性，提示其作为治疗靶点的潜力。
2. **文献名称**：*Development of a Monoclonal NRIP1 Antibody for Metabolic Tissue Analysis*
**作者**：Chen L, et al.
**摘要**：报道一种新型小鼠单克隆NRIP1抗体的开发与验证，应用于脂肪组织和肝脏样本的免疫荧光染色，揭示NRIP1在调控脂质代谢中的组织特异性表达模式。
3. **文献名称**：*NRIP1 Knockdown and Antibody Validation in Ovarian Cancer Models*
**作者**：Wang Y, et al.
**摘要**：通过siRNA沉默NRIP1基因，结合商业化NRIP1抗体进行流式细胞术分析，证明NRIP1高表达与卵巢癌细胞化疗耐药性相关，机制涉及NF-κB通路激活。
4. **文献名称**：*ChIP-Seq Analysis Using NRIP1 Antibody Reveals Genome-Wide Binding Sites*
**作者**：Kim T, et al.
**摘要**：采用ChIP-seq技术结合特异性NRIP1抗体，系统绘制NRIP1在人类基因组中的结合位点，发现其优先结合代谢相关基因启动子区域，调控糖酵解和氧化磷酸化过程。
---
**建议**：如需真实文献，可通过PubMed或Google Scholar搜索关键词“NRIP1 antibody”、“RIP140 antibody application”等，并筛选涉及实验方法学(如Western blot、IHC)的研究。
**Background of NRIP1 Antibody**
The Nuclear Receptor Interacting Protein 1 (NRIP1), also known as RIP140 (Receptor-Interacting Protein 140), is a transcriptional coregulator that modulates the activity of nuclear receptors and other transcription factors. It plays a critical role in diverse biological processes, including energy metabolism, reproduction, and circadian rhythm regulation. NRIP1 interacts with ligand-bound nuclear receptors (e.g., estrogen receptor, thyroid hormone receptor) to either enhance or repress their transcriptional activity, depending on cellular context. Dysregulation of NRIP1 has been implicated in metabolic disorders, cancer progression, and reproductive abnormalities.
Antibodies targeting NRIP1 are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence to investigate NRIP1's role in cellular pathways and disease mechanisms. Commercial NRIP1 antibodies are typically raised against specific epitopes (e.g., human or mouse-derived peptide sequences) and validated for specificity and sensitivity across applications. Research utilizing these antibodies has advanced understanding of NRIP1's dual role as a coactivator or corepressor in hormone signaling and its potential as a therapeutic target in metabolic syndromes and hormone-dependent cancers. Quality validation, including knockout controls, is crucial to ensure antibody reliability in experimental settings.
×
